it gained 9.19% and traded over 209 thousand shares on the market.According to the historical data, NWBO has been going up and down all the time, while its current trading range varies between $0.83 – $0.95 per share. Though, presently no particular reason for the climb can be found.
Last month, Northwest reported the positive follow-up data from its prior clinical trials, though since then the company has not released any announcements, except the report on its financials. According to it, “The Company has experienced recurring losses from operations, and as of June 30, 2010 had a working capital deficit of $19.6 million and a deficit accumulated during the development stage of $204.5 million”. Besides, NWBO has not generated any revenue and gross profit and has suffered a net loss of over $3 thousand.[BANNER]
The company’s total assets are about 50 times lower than its liabilities, while its stockholders’ equity has increased. Northwest has issued 100 thousand shares of its common stock, however, it still has a long-term debt to cover.
According to these financial results, the company will definitely need “to raise additional capital in the near future to fund its clinical trials and other operating activities”. While, in the meantime, the present up move of NWBO stock is not certain.
